World Congress on Thyroid Cancer 3.5
Rome, Italy | 2019
World Congress on Thyroid Cancer 4.0
July 29 – August 1, 2021
WCTC3.5 Steering Committee:
Rocco Bellatone, Co-Chair
Celestino Lombardi, Co-Chair
Gregory W. Randolph, MD
Bryan McIver, MD
Jeremy Freeman, MD
Ian J. Witterick, MD
Ashok R. Shaha, MD
Jatin P. Shah, MD
OP67 – Clinical Impact of minimal extrathyroidal extension and others clinical factors as independent risk of recurrence and persistence disease in 1351 patients with papillary thyroid cancer
Ozorio de Almeida, Maria Fernanda1; Ticly, Ana Luiza1; Ferraz, Carolina1; Cury, Adriano Namo1; Guardia, Vivian Cenize1; Scalissi, Nilza Maria1; Morone, Marília2; Padovani, Rosália do Prado1,2
1 Endorinology Unit, Internal Medicine Department of Santa Casa de Sao Paulo, School of Medical Sciences
2 Nuclear Medicine Service of Santa Casa de Sao Paulo, School of Medical Sciences
Background/Purpose: According to initial risk stratification proposed by 2015 American Thyroid Association (ATA) guideline, some clinic pathologic characteristics are response to increase the risk of recurrence/ persistence papillary thyroid cancer (PTC). Minimal extrathyroidal extension (mETE) is recognized as an isolated risk factor for poor prognosis. However, the impact of mETE as a prognostic independent risk factor remains controversial. The objective of this study is assess the impact of the mETE and others factors (sex, tumor size, age at diagnosis, multicentricity, radioactive iodine activity and initial stimulated thyroglobulin values) on PTC.
Methods: 1351 PTC patients seen at the Nuclear Medicine Division at Santa Casa de São Paulo were included in this retrospective study and were classified as low risk or intermediate risk of recurrence just due the presence of mETE. Next, patients were divided according to underwent or not RAI therapy. Patients were classified according to the response to initial treatment using the ongoing risk stratification. Besides mETE, others risk factors were evaluated. Statistical analysis was made using SPSS 13.0 and qui-square and Mann-Whitney test.
Results: mETE itself didn´t have impact on the response to initial therapy (p0.37) as others factors like sex (p0.85), multicentricity (p0.07) and age (p0,27). Greater tumor size (p0,02) and initial thyroglobulin >10ng/dL(p0.00) were associated with worst prognosis.
Discussion & Conclusion: This study suggests that METE itself cannot be associated with risk of persistent/recurrent disease in DTC patients. Meanwhile the tumor size and the initial thyroglobulin value (>10ng/mL) are associated with poor prognosis suggesting more aggressive therapy and close follow-up.
- Shin JH, Ha TK, Park HK, Ahn MS, Kim KH, Bae KB, Kim TH, Choi CS, Kim TK, Bae SK, Kim SH. Implication of minimal extrathyroidal extension as a prognostic factor in papillary thyroid carcinoma. Internacional Journal of Surgery 11 (2013) 944-947.
- Ito Y, Tomada C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A. Minimal exrathyroid extension does not affect the relapse-free survival of patients with papillary thyroid carcinoma measuring 4cm or less over the age of 45 years. Surgery Today (2006) 36:12-18.
- Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A. Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival.
- Hu A, Clark J, Payne RJ, Eski S, Walfish PG, Freeman JL. Exrathyroidal extension in well-differentiated thyroid cancer: macroscopic vs microscopic as a predictor outcome. Arch Otolaryngol Head Neck Surg. 2007; 133(7): 644-649.
- Buffet C, Golmard JL, Hoang C, Trésallet C, Fédiaevsky LDP, Fierrard H, Aurengo A, Menegaux F, Leenhardt L. Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma. European Journal of Endocrinology (2012) 167 267-275.
- Lee CY, Kim SJ, Ko KR, Chung K-W, Lee J-H. Predictive factors for extrathyroidal extension of papillary thyroid carcinoma based on preoperative sonography. American Institute of ultrasound in medicine 2014; 33:231-238.
- Moon HJ, Kim E-K, Chung WY, Yoon JH, Kwak JY. Minimal extrathyroidal extension in patients with papillary thyroid microcarcinoma: is it a real prognostic factor?. Ann Surg Oncol (2011) 18: 1916-1923.
- Kim JM, Lee YY, Choi CW, Lim SM, Lee S-S, Cho SY, Lee GH, Lee B-C, Yi KH. The clinical importance of minimal exrathyroid extension on tumor recurrence in patients with papillary thyroid carcinoma. Endocrinol Metab 25(4): 340-346, December 2010.
- Maia AL, Ward LS, Carvalho GA, Graf H, Maciel RMB, Maciel LMZ, Rosário PW, Vaisman M, Nódulos de tireóide e câncer diferenciado de tireóide: consenso brasileiro. Arq Bras Endocrinol Metab vol. 51 n.5. São Paulo July 2007.
- Alexander EK, Bible KC, Doherty GM, Tuttle RM et al. American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differenciated Thyroid Cancer. Thyroid 2015: 1-411.